Conference
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.
Authors
Gelmon KA; Hirte HW; Robidoux A; Tonkin KS; Tischkowitz M; Swenerton K; Huntsman D; Carmichael J; Macpherson E; Oza AM
Volume
28
Pagination
pp. 3002-3002
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2010
DOI
10.1200/jco.2010.28.15_suppl.3002
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X